newsfilter
← Latest News
Business Wire·

Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that data on XERAVA will be featured in seven poster presentations at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week (IDWeek) 2019, taking place October 2-6 in Washington, DC, at the Walter E. Washington Convention Center.